Skip to main content
. Author manuscript; available in PMC: 2025 Apr 1.
Published in final edited form as: Transl Stroke Res. 2023 Jan 23;15(2):446–461. doi: 10.1007/s12975-023-01124-w

Fig. 4.

Fig. 4

Flow cytometry graphs show in male (a) and female (b) a significant increase in the pNOS3 and pAMPK counts with one month of EXR therapy in BCAS+EXR groups compared to the BACS group. Histograms on the left upper panel for pNOS3 and pAMPK and the right upper panel for M1 & M2 for both male (a) and female (b) show the isotype controls (shaded grey-filled graphs). Histogram at the left bottom panel (4a, i-iii) glycophorin, pNOS3 and pAMPK for male; and right bottom panel (4b, i-iii) glycophorin, pNOS3 & pAMPK for female. The X axis is the relative fluorescence (light scatter intensity) and Y axis is the number of events (cell counts). For dot plots, the scales are relative fluorescence (light scatter intensity) on both axes. Values are indicated as means ±SEM from 5 mice /group for each sex and were analyzed by a one-way ANOVA test followed by Bonferroni’s multiple comparison tests. Comparison of each group for male 4a (i) **p=0.0011 sham vs BCAS; *p=0.0157 BCAS vs BCAS+EXR; 4a (ii) ***p=0.0007 sham vs BCAS; *p=0.0201 BCAS vs BCAS+EXR; 4a (iii) ****p<0.0001 sham vs BCAS; ***p=0.0009 BCAS vs BCAS+RXR; ns, not significant; and comparison of each group for female 4b (i) **p=0.0014 sham vs BCAS; *p=0.0373 BCAS vs BCAS+EXR; 4b (ii) **p=0.0016 sham vs BCAS; *p=0.0199 BCAS vs BCAS+EXR; 4b (iii) ****p<0.0001 sham vs BCAS; ***p=0.0005 BCAS vs BCAS+RXR; ns, not significant.